SCHEMBL3104769

SCHEMBL3104769

Cc1cccc(NC(=O)c2cc(Cl)cc(C)n2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN2A Q99250 1/20 0.57
SCN10A Q9Y5Y9 1/20 0.57
SMN1; SMN2 Q16637 5/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
LMNA P02545 2/20 0.57
ALDH1A1 P00352 1/20 0.57
RXFP1 Q9HBX9 1/20 0.55
KCNK3 O14649 3/20 0.55
KCNK9 Q9NPC2 2/20 0.55
RAB9A P51151 3/20 0.53
NPC1 O15118 2/20 0.53
GBA1 P04062 1/20 0.53
MAPK1 P28482 1/20 0.53
GAA P10253 2/20 0.53
TP53 P04637 3/20 0.52
F12 P00748 2/20 0.52
HSD17B10 Q99714 1/20 0.51
KCNH2 Q12809 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7900424 0.90 ALDH1A1 (0.59) SMN1; SMN2MEN1KMT2ALMNAALDH1A1
SCHEMBL23413329 0.89 GAA (0.60) SCN2ASCN10ASMN1; SMN2MEN1KMT2A
SCHEMBL30097611 0.89 GAA (0.60) SCN2ASCN10ASMN1; SMN2MEN1KMT2A
SCHEMBL7913043 0.86 SMN1; SMN2 (0.67) SMN1; SMN2MEN1KMT2ALMNAKCNK3
SCHEMBL3101805 0.81 SMN1; SMN2 (0.52) SCN2ASCN10ASMN1; SMN2MEN1KMT2A
SCHEMBL13148167 0.81 SMN1; SMN2 (0.52) SCN2ASCN10ASMN1; SMN2MEN1KMT2A
SCHEMBL7913044 0.80 SORT1 (0.58) SMN1; SMN2MEN1KMT2ARAB9ANPC1
SCHEMBL30097521 0.79 SMN1; SMN2 (0.52) SCN2ASCN10ASMN1; SMN2MEN1KMT2A
SCHEMBL23413371 0.79 SMN1; SMN2 (0.52) SCN2ASCN10ASMN1; SMN2MEN1KMT2A
SCHEMBL14200525 0.79 KCNK3 (0.73) SMN1; SMN2MEN1KMT2ALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010100050-A1 PYRIDINE-2-YL-CARBOXYLIC ACID AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2010-09-10 WO claimed
US-20100227887-A1 PYRIDINE-2-YL CARBOXYLIC ACID AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2010-09-09 US claimed
WO-2010100050-A1 PYRIDINE-2-YL-CARBOXYLIC ACID AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2010-09-10 WO disclosed
WO-2010100050-A1 PYRIDINE-2-YL-CARBOXYLIC ACID AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2010-09-10 WO disclosed
US-20100227887-A1 PYRIDINE-2-YL CARBOXYLIC ACID AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2010-09-09 US disclosed
US-20100227887-A1 PYRIDINE-2-YL CARBOXYLIC ACID AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2010-09-09 US disclosed
US-20100227887-A1 PYRIDINE-2-YL CARBOXYLIC ACID AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227887-A1 PYRIDINE-2-YL CARBOXYLIC ACID AMIDES GRM2, GRM1, GRM3 SCN2A 831/4885SCN10A 1565/4885SMN1; SMN2 2966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.